Repeated adrenaline doses and survival from an out-of-hospital cardiac arrest.

BACKGROUND: Adrenaline is the primary drug of choice for resuscitation from out-of-hospital cardiac arrest (OHCA). Although adrenaline may increase the chance of achieving return of spontaneous circulation (ROSC), there is limited evidence that repeated doses of adrenaline improves overall survival, and increasing evidence of a detrimental effect on neurological function in survivors. This paper reports the relationship between repeated doses of adrenaline and survival in a cohort of patients attended by the London Ambulance Service in the United Kingdom. METHODS: A retrospective review of OHCA treated by the London Ambulance Service over a one year period. Patients aged ≥18 years who received one or more doses of adrenaline (1 mg bolus) during resuscitation were included in the analyses. Outcomes described are survival to hospital discharge and survival to one year post-arrest. RESULTS: Over the one year study period, 3151 patients received adrenaline during OHCA. A significant inverse relationship was found between increasing cumulative doses of adrenaline and survival both to hospital discharge and one year post-arrest. No patients survived after receiving more than ten adrenaline doses. CONCLUSION: Our study indicates that repeated doses of adrenaline are associated with decreasing odds of survival. There were no survivors amongst patients requiring more than 10 doses of adrenaline.

Double sequential defibrillation therapy for out-of-hospital cardiac arrests: The London experience.

BACKGROUND: Despite advances in treatment for out-of-hospital cardiac arrest (OHCA), a subgroup of patients remain in refractory ventricular fibrillation (RVF) during resuscitation. Recent evidence suggests that double sequential defibrillation (DSD), where two shocks are delivered to the patient in quick succession, may provide an effective therapy for RVF. This study describes the characteristics and survival outcomes of OHCA patients treated by ambulance clinicians using a local DSD protocol in an attempt to resolve RVF. METHODS: This is a retrospective, observational analysis of patients who received DSD by the London Ambulance Service from 1st July 2015 to 31st December 2016. A comparator group of patients who received more than six consecutive standard shocks (not DSD) for persistent VF was also identified. Outcomes included pre-hospital return of spontaneous circulation (ROSC), ROSC sustained to hospital, and survival to hospital discharge. DSD patients who survived to hospital discharge are reported in further detail. RESULTS: During the 18-month study period, 45 patients were treated with DSD: a third obtained a pre-hospital ROSC and 7% survived to hospital discharge. We observed similar ROSC and survival rates amongst those who received standard defibrillation only. CONCLUSION: Our observational study did not find any clear benefit of DSD use by EMS in the treatment of RVF. However, we find that 3 patients, who were treated with DSD following unsuccessful single shocks, had their VF terminated. Prospective randomised clinical trials are urgently needed to investigate the potential value of DSD in the pre-hospital setting.